罗群英,甘炜坚,余靖华,刘泳珊
LUO Qunying,GAN Wei Jian,YU Jinghua,LIU Yongshan

• 1:南方医科大学附属南海医院

摘要(Abstract)：

目的对莫西沙星、左氧氟沙星静脉口服序贯方法治疗住院患者治疗社区获得性肺炎进行经济学评价,选择更有经济学价值的治疗方案。方法应用成本效果法对莫西沙星和左氧氟沙星关于序贯疗法治疗社区获得性肺炎进行分析。对符合纳入标准文献(共入选9篇文献)进行统计分析,以临床治疗有效率、细菌清除率作为疗效指标进行药物经济学评价。结果以临床治疗有效率为疗效指标时,莫西沙星的成本较高,疗效较差。以细菌清除率作疗效指标时,选用最小成本法分析,莫西沙星的治疗成本为2 458.97元,左氧氟沙星的治疗成本为1 697.75元,左氧氟沙星的治疗成本较低。结论在序贯治疗法治疗社区获得性肺炎方面上,从临床治疗有效率和细菌清除率的疗效治疗评价,左氧氟沙星的经济价值都比莫西沙星高。
OBJECTIVE To evaluate the pharmacoeconomic effect of moxifloxacin and levofloxacin in the sequential IV / PO treatment of community-acquired-pneumonia( CAP),so as to choose the treatment programs with higher economic value. METHODS Cost effective method of moxifloxacin and levofloxacin in Sequential IV / PO treatment of CAP were analyzed. The clinical effectiveness and bacterial clearance rates were collected from the inclusion criteria literature( a total of 9 selected literature) by statistical analysis.RESULTS When the clinical effective rate was used as therapeutic effect index,the effect of moxifloxacin was worse and the cost was higher. When the bacterial clearance rate was used as therapeutic effect index,the cost of moxifloxacin was 2 458. 97 yuan and that of levofloxacin was 1 697. 75 yuan. CONCLUSION For the sequential IV / PO treatment of CAP,when the clinical effective rate and bacterial clearance rate were used as therapeutic effect index,the economic value of levofloxacin is better than moxifloxacin.

关键词(KeyWords)： 莫西沙星;左氧氟沙星;社区获得性肺炎;经济学评价
moxiflaxacin;levofloxacin;community-acquired pneumonia;pharmacoeconomic evaluation

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 罗群英,甘炜坚,余靖华,刘泳珊
LUO Qunying,GAN Wei Jian,YU Jinghua,LIU Yongshan

参考文献(References)：

• [1]何礼贤,肖永红,陆权,等.国家抗微生物治疗指南[M].北京:人民卫生出版社,2012:12-14.
• [2]谭星宇,何权瀛,王月珠,等.362例社区获得性肺炎患者住院费用调查[J].中华医院管理杂志,2002(7):32-35.
• [3]Anzueto A,Niederman MS,Pearle J,et al.Community-Acquired Pneumonia Recovery in the Elderly(CAPRIE):efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy[J].Clin Infect Dis,2006,42(1):73-81.
• [4]Finch R,Schurmann D,Collins O,et al.Randomized controlled trial of sequential intravenous(i.v.)and oral moxifloxacin compared with sequential i.v.and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment[J].Antimicrob Agents Chemother,2002,46(6):1746-1754.
• [5]Katz E,Larsen L S,Fogarty C M,et al.Safety and efficacy of sequential i.v.to p.o.moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v.therapy[J].J Emerg Med,2004,27(4):395-405.
• [6]Torres A,Garau J,Arvis P,et al.Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia:the MOTIV study——a randomized clinical trial[J].Clin Infect Dis,2008,46(10):1499-1509.
• [7]Welte T,Petermann W,Schurmann D,et al.Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy[J].Clin Infect Dis,2005,41(12):1697-1705.
• [8]Carratala J,Fernandez-Sabe N,Ortega L,et al.Outpatient care compared with hospitalization for community-acquired pneumonia:a randomized trial in low-risk patients[J].Ann Intern Med,2005,142(3):165-172.
• [9]Fogarty C,Siami G,Kohler R,et al.Multicenter,Open-Label,Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adults[J].Clinical Infectious Diseases,2004,38(Suppl 1):S16-S23.
• [10]邵长周,何礼贤,王广发,等.左氧氟沙星序贯疗法与头孢呋辛联合阿奇霉素治疗社区获得性肺炎的多中心、随机对照临床和药物经济学研究[Z].2008102-106.
• [11]巫翠华,杜秀芳,林映花,等.左氧氟沙星与莫西沙星治疗老年社区获得性肺炎的成本-效果分析[J].实用临床医药杂志,2011(15):91-93.
• [12]王全洪,何勇,王玉和.莫西沙星注射液与左氧氟沙星注射液随机对照治疗社区获得性肺炎药物经济学评价[J].中国药物经济学,2013(03):36-39.
• [13]黄健虹,蔡笑珊,邓智武,等.莫西沙星注射液与左氧氟沙星注射液治疗社区获得性肺炎的药物经济学分析[J].天津药学,2009(02):46-47.
• [14]孟静娟.新抗生素莫西沙星国内外研究应用最新进展[J].微生物学杂志,2007(05):98-101.
• [15]邢颖,卞婧,甄健存.莫西沙星和左氧氟沙星治疗社区获得性肺炎有效性和安全性的Meta分析[J].中国医院药学杂志,2011(05):414-416.